Service Evaluation for Newborn Screening for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a rare inherited condition that causes progressive muscle weakness. In its most severe form, it affects young babies and can be life-threatening without treatment. New medicines can prevent severe disability and save lives, but they work best when started before symptoms appear. In this NHS study, seven regional screening laboratories will test babies for SMA using their routine newborn heel-prick blood sample. Parents will be asked for their permission, and no extra blood is taken. Researchers will assess how well the screening works, whether diagnosed babies receive treatment sooner, and if it helps them reach key physical milestones like walking. They will also look at costs and ask parents for their views. The results will help the UK National Screening Committee decide if all UK newborns should be screened for SMA in the future.
De un vistazo
¿De qué trata este estudio?
Spinal muscular atrophy (SMA) is a rare genetic condition that damages the nerve cells controlling our muscles. Over time, this leads to muscle weakness and wasting. For babies with the most severe form, it can cause serious problems with moving, breathing, and swallowing early in life. Fortunately, newer NHS treatments can slow down or prevent this muscle damage. These medicines are most effective when given as early as possible, ideally before any signs of weakness develop.
Currently, newborn babies in the UK have a routine 'heel-prick' blood spot test around five days after birth to check for several rare conditions. SMA is not yet included in this routine check. Led by the University of Oxford alongside NHS hospitals, this study will evaluate whether adding SMA screening to the newborn test is practical, reliable, and beneficial.
The project will gradually roll out across seven NHS laboratory regions, covering around 400,000 births each year. By comparing babies born before and after screening begins, researchers hope to see if early detection helps children reach major milestones, such as walking independently by age two. The study will also assess whether the screening is cost-effective for the NHS and acceptable to parents from all backgrounds.
Puntos clave
- The study tests whether adding SMA to the UK routine newborn heel-prick test improves long-term health.
- Treatments for SMA are available on the NHS and work best before symptoms appear.
- No extra blood samples or needle pricks are needed to take part.
- Screening will roll out in seven NHS laboratory regions between 2026 and 2030.
- The evidence gathered will help decide if SMA screening should be offered to every baby across the UK.
¿Quién puede ser elegible?
This study is open to newborn babies born in areas covered by the seven participating NHS screening laboratories between autumn 2026 and autumn 2030. To take part in the screening, parents or guardians must give their permission when their baby has their routine newborn blood spot test.
The study also follows children diagnosed with SMA between late 2024 and 2030, whether they were identified through this new screening test or through standard hospital care after symptoms started. This allows doctors to compare how children diagnosed early through screening progress compared to those diagnosed later.
In addition, parents of babies who are screened—including those whose babies test negative and those who decide not to take part—may be invited to share their views in a feedback study to help researchers understand family experiences.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Your baby is born in an NHS region covered by one of the seven participating screening laboratories.
- Your baby is due to have their routine day-5 newborn blood spot (heel-prick) test between autumn 2026 and autumn 2030.
- You are happy to give consent for the laboratory to check the blood spot for SMA.
- Or, your child has received a confirmed diagnosis of SMA through NHS care between late 2024 and 2030.
¿En qué consiste la participación?
Joining the screening part of the study is designed to be straightforward for new parents. When your baby has their routine NHS heel-prick blood test around five days after birth, you will be asked if you consent to the extra SMA check. Because the laboratory uses the blood already collected on the standard card, your baby will not need any extra needle pricks or extra clinic visits.
If the screening test is clear, you will receive results through the usual NHS screening route, and no further steps are needed. If the test suggests your baby might have SMA, you will be contacted quickly by a specialist NHS team for confirmatory tests and to discuss starting treatment right away.
For babies diagnosed with SMA, long-term health and development (such as reaching motor milestones) will be tracked through regular clinic appointments that form part of their normal care and through the national SMA REACH network. Parents may also be asked to complete occasional questionnaires about their family's health and well-being over the child's early years.
Riesgos y beneficios potenciales
Locations (3)
- Kings College LondonCódigo postal verificadoLondres, Reino Unido· Reclutamiento
- Universidad de OxfordCódigo postal verificadoOxford, Reino Unido· Aún no reclutando
- Universidad de WarwickCódigo postal verificadoWarwick, United Kingdom· Reclutamiento
Preguntas comunes
Will my baby need an extra needle prick for this test?
No. The laboratory tests the blood drops that are already collected for the routine day-five newborn heel-prick test.
What happens if the screening test suggests SMA?
An NHS specialist doctor will contact you promptly to arrange follow-up genetic testing to confirm the result and discuss starting treatment as soon as possible.
Do I have to take part in this study?
No. Taking part is completely optional. Your midwife will ask for your consent, and your baby will still receive all their standard NHS care if you choose not to take part.
How common is spinal muscular atrophy?
SMA is rare, affecting roughly 1 in every 10,000 babies born. Most babies tested will receive a normal (negative) result.
When will we get the screening results?
Results are handled alongside your baby's normal newborn screening checks, usually within a few weeks. If an issue is suspected, parents are contacted directly and quickly.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.